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http://dxObjective: We sought to determine whether ventilation of lungs after death in non–heart-beating donors with
carbon monoxide during warm ischemia and ex vivo lung perfusion and after transplant would reduce ische-
mia-reperfusion injury and improve lung function.
Methods: One hour after death, Sprague-Dawley rats were ventilated for another hour with 60% oxygen (con-
trol group) or 500 ppm carbonmonoxide in 60% oxygen (CO-vent group; n¼6/group). Then, lungs were flushed
with 20 mL cold Perfadex, stored cold for 1 hour, then warmed to 37C in an ex vivo lung perfusion circuit
perfused with Steen solution. At 37C, lungs were ventilated for 15 minutes with alveolar gas with or without
500 ppm carbon monoxide, then perfusion-cooled to 20C, flushed with cold Perfadex and stored cold for
2 hours. The left lung was transplanted using a modified cuff technique. Recipients were ventilated with
60% oxygen with or without carbon monoxide. One hour after transplant, we measured blood gases from the
left pulmonary vein and aorta, and wet-to-dry ratio of both lungs. The RNA and protein extracted from graft
lungs underwent real-time polymerase chain reaction and Western blotting, and measurement of cyclic guano-
sine monophosphate by enzyme-linked immunosorbent assay.
Results: Carbon monoxide ventilation begun 1 hour after death reduced wet/dry ratio after ex vivo lung perfu-
sion. After transplantation, the carbon monoxide–ventilation group had better oxygenation; higher levels of
tissue cyclic guanosine monophosphate, heme oxidase-1 expression, and p38 phosphorylation; reduced c-Jun
N-terminal kinase phosphorylation; and reduced expression of interleukin-6 and interleukin-1bmessenger RNA.
Conclusions: Administration of carbon monoxide to the deceased donor and non–heart-beating donor lungs
reduces ischemia-reperfusion injury in rat lungs transplanted from non–heart-beating donors. Therapy to the




SSupplemental material is available online.
Lung disease is the third most common cause of death in the
United States. Lung transplantation (LTX) successfully pal-
liates patients with end-stage lung disease. However, in
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The Journal of Thoracic and CaUnited States, and 235 patients died on the waiting list
because of the critical shortage of suitable lungs from con-
ventional organ donors. As a result of this donor shortage,
strict listing criteria are espoused; many end-stage lung dis-
ease patients are not even considered candidates for trans-
plant. We have been investigating the use of Maastricht
category I non–heart-beating donors (NHBDs) as a possible
solution to the lung donor shortage.1,2 These donors are
individuals who die outside the hospital from cardiac arrest
or as a result of trauma. Using NHBDs as lung donors
would eliminate the lung shortage and allow many more
patients with end-stage lung disease to undergo LTX.
Because of variable warm ischemic times and other pre-
morbid events, lungs retrieved from NHBDs need to be
assessed before transplant. Steen3 developed amethod to per-
fuse and ventilate lungs ex vivo to evaluate lung function be-
fore transplant.We and others developed similar ex vivo lung
perfusion (EVLP) circuits to evaluate human lungs retrieved
from conventional donors determined unacceptable for
transplantation, or lungs from donation-after-cardiac-death
donors (DCDs).4,5 Steen6 used his EVLP system to evaluate
lungs retrieved from conventional donors initially turned
down for transplant, and successfully transplanted 6 lungs af-
ter EVLP.5 Keshavjee’s group7 modified EVLP by closingrdiovascular Surgery c Volume 146, Number 2 429
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cGMP ¼ cyclic guanosine monophosphate
CO ¼ carbon monoxide
DCD ¼ donation-after-cardiac-death donor
ERK ¼ extracellular signal-regulated kinase
EVLP ¼ ex vivo lung perfusion
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IL ¼ interleukin
IkBa ¼ nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha
iNOS ¼ inducible nitric oxide synthase
IRI ¼ ischemia–reperfusion injury
JNK ¼ c-Jun N-terminal kinase
LTX ¼ lung transplantation
MAPK ¼ mitogen-activated protein kinase
mRNA ¼ messenger RNA
NHBD ¼ non–heart-beating donor
NF-kB ¼ nuclear factor kappa B
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PA ¼ pulmonary artery
TNF ¼ tumor necrosis factor




Sthe left atrium to provide positive left atrial pressure. This en-
abled perfusion of human lungs ex vivo for prolonged pe-
riods. Keshavjee’s group reported 20 successful LTXs after
EVLP using lungs initially judged unsuitable for transplant.6
We developed a translational model of EVLP to rewarm,
perfuse, and ventilate rat lungs retrieved from NHBDs be-
fore LTX.8 Using this model, we showed that administration
of nitric oxide (NO) to NHBDs before and after lung re-
trieval reduced edema when lungs were perfused in the
ex vivo circuit, reduced pulmonary vascular resistance,
and improved oxygenation after transplant.9
In the current study, we show that ventilation of NHBD
lungs with another gaseous second messenger, carbon mon-
oxide (CO), after death during warm ischemia in the
deceased donor, during EVLP, and postoperatively, reduces
ischemia–reperfusion injury (IRI) and improves post-LTX
function of lungs retrieved from NHBDs.
METHODS
Donor Lung Retrieval and the Ex Vivo Circuit
Specific details of donor lung retrieval and the rat EVLP circuit have
been described.8,9 Briefly, male Sprague-Dawley rats (350-450 g) were
anesthetized with intraperitoneal pentobarbital (7.5 mg/100 g; Abbott
Laboratories, Chicago, Ill). After tracheotomy, laparotomy exposed the
liver for intrahepatic injection of heparin (600 U; Elkins-Sinn, Cherry
Hill, NJ). Donor rats were sacrificed with intrahepatic pentobarbital
(15 mg/100 g). One hour after cardiac arrest, dead rats were ventilated for
another hour with 60% O2 alone (control, n ¼ 6) or 500 ppm CO in 60%
O2 (CO-vent, n¼ 6) with a tidal volume of 0.75mL/100 g, a rate of 70/min-
ute, and a positive end-expiratory pressure of 3 cm H2O. Because of the lo-
gistics in setting up the ventilation circuit, all control donor–recipient pairs430 The Journal of Thoracic and Cardiovascular Surgwere studied before the CO-vent pairs. Assignment as donor or recipient
within size-matched pairs was arbitrary. Via median sternotomy, the right
ventricle was cannulated with p60 tubing and the left atrial appendage
was incised to vent the pulmonary circulation. The lungs were flushed
with 20 mL cold Perfadex (Vitrolife, Kungsbacka, Sweden) and stored at
4C for 1 hour. The lung block was removed from cold storage, perfused
in an ex vivo circuit with 90 mL Steen solution (Vitrolife) through the pul-
monary artery (PA) using a Minipuls-3 peristaltic pump (Gilson Medical
Electronics, Middleton, Wis). Circuit perfusate temperature was manipu-
lated by circulating water through a Plexiglas–jacketed reservoir with
a pump, positioned in a cooler containing either warm (38C) or ice-cold
water. Pulmonary artery and airway pressure were monitored continuously
with transducers attached to National Instruments (Austin, Tex) hardware
connected to a computer with continuous real-time display. Perfusion
flow rate (3.5 mL 3 body weight [grams]/100) was adjusted to maintain
PA pressure below 20 mm Hg. When the circuit temperature reached
37C, the lungs were ventilated mechanically (Harvard rodent respirator
model 681; Harvard Apparatus Co, Millis, Mass) with alveolar gas (5%
CO2, 20% O2, 75% N2) for controls and 500 ppm CO in alveolar gas for
the CO-vent group at 60 breaths/minute, with a tidal volume of 0.75 mL/
100 g. Perfusate pHwasmonitored continuously with an Acumen pH probe
(Fisher Scientific, Pittsburgh, Pa) in the venous reservoir. The pHwasmain-
tained near 7.40 by adding dilute HCl or NaHCO3 as necessary. Ventilation
and perfusion continued for 15 minutes at 37C to simulate ex vivo gas
exchange assessment. The lungs were then perfusion-cooled to 20C,
flushed again with cold Perfadex, and stored cold for 2.5 hours. The left
lung was then transplanted. The right lung was used to evaluate post-
EVLP edema.
Rat Lung Transplantation Technique
Left LTXwas performedusing amodified cuff technique.8,9After EVLP,
the right bronchus was ligated and the trachea was retrieved with the left
lung so the left lung could be ventilated separately after transplant. The
transplanted left lung and the recipient’s right lung were then both
ventilated with 60% O2 with or without CO. Transonic Systems (Ithaca,
NY) flow probes were placed on the left and main PAs before sacrifice 1
hour after transplant.
Outcome Measures
Outcomes were evaluated as described previously.8 Lung function was
assessed by a wet-to-dry weight ratio, measured arterial pO2/fractional in-
haled oxygen concentration, airway pressure, and left PA flow per total PA
flow normalized by the donor-to-recipient weight ratio. Western blots for
extracted proteins quantified nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha (IkBa) concentration and phos-
phorylation of 3 mitogen-activated protein kinases (MAPK): p38, c-Jun
N-terminal kinase (JNK), and extracellular signal-regulated kinase
(ERK). IkBa, p38, JNK, and ERK were expressed as blot intensity (Im-
ageJ software; National Institutes of Health, Bethesda, Md) in ratio to in-
tensity of actin or total p38, JNK, and ERK. Lung protein extracted from
normal rats and flash-frozen immediately after death was evaluated to
demonstrate normal levels of IkBa, and MAPK phosphorylation in fresh
lung tissue. Cyclic guanosine monophosphate (cGMP) was measured by
enzyme-linked immunosorbent assay. Real-time reverse transcription–
polymerase chain reaction quantified upregulation of lung messenger
RNA (mRNA) for interleukin (IL)-6, IL-1b, heme oxygenase-1 (HO-1),
tumor necrosis factor-a (TNF-a), intercellular adhesion molecule 1, endo-
thelial nitric oxide synthase, inducible nitric oxide synthase (iNOS), and
B-cell lymphoma 2. Primers for reverse transcription–polymerase chain
reaction are shown in online Table E1. Tissues were stained for nuclear
localization of p65 component of nuclear factor kappa B (NF–kB). Out-
comes were evaluated before and after EVLP, 1 hour after LTX, and in
fresh lung tissue obtained from 6 control donors immediately after
sacrifice.ery c August 2013
Dong et al Evolving Technology/Basic ScienceStatistical Analyses
The primary analyses relied on graphical methods and analysis of var-
iance for paired and nonpaired responses. For 17 interval-scale outcomes,
estimates of mean response 1 standard error are shown. Statistical tests of
the primary null hypothesis—treatment effect is 0—were performed with-
out multiple-comparisons adjustment. For balanced comparisons (eg, n¼ 6
controls, n¼ 6 CO-vent) pooled-variance t tests of size a¼ 0.05 were used;
otherwise, the Satterthwaite t test was used. Supportive analyses explored
robustness of the results to statistical methods (eg, analysis of median IL-6
vs analysis of mean IL-6). All computations were performed using SAS 9.2
software (SAS Institute, Cary, NC).
Animal Care
The University of North Carolina Institutional Animal Care and Use
Committee approved the protocol for this study. All animals received hu-
mane care in accordancewith theGuide for the Care andUse of Laboratory
Animals.10SRESULTS
Lung Function
After EVLP, CO-ventilated lungs from NHBDs devel-
oped less edema (P ¼ .0356) than lungs ventilated with
O2; however, 1 hour after transplant the difference was neg-
ligible (Figure 1, A). The CO-vent treatment improved left
pulmonary vein oxygenation 1 hour after transplant
(P ¼ .0058), but a treatment effect was not detected
(P ¼ .61) for aorta oxygenation (Figure 1, B). Effects of
CO-vent treatment were not detected (P ¼ .65) for the
left:main PA flow ratio (Figure 1, C) and for graft airway




Mean cGMP 1 hour after LTX in graft lungs was higher in
the CO-vent group (P ¼ .0358) (Figure 2), whereas a treat-
ment effect was not detected in recipients’ right lungs
(P ¼ .22, n ¼ 6 CO-vent, n ¼ 5 controls) (not shown).function. A, After perfusion in the circuit, donor lungs ventilated with
500 ppm CO/60% oxygen (CO-vent) developed less edema than controls
(Ctrl), which were ventilated with 60% oxygen (*P¼ .036). One hour after
lung transplant, the mean wet-to-dry weight ratio was similar in CO-vent
and control lungs. B, After transplant, oxygenation in CO-ventilated graft
lungs was better than in control lungs (yP = .0058). C, Flow to the graft lung
(L) expressed as a ratio to total flow [LPA = (LPA flow rate/donor weight)/
(PA flow rate/recipient weight)] was similar in the 2 groups (P ¼ .14). The
mean  1 standard error is shown for control lungs (n ¼ 6) and CO-vent
(n¼ 6). R, Right; Recip, recipient; PaO2/FiO2, measured arterial pO2/frac-
tional inhaled oxygen concentration; LPV, left pulmonary vein; LPA, left
pulmonary artery; PA, pulmonary artery.Immunoblotting for IkBa and Mitogen-Activated
Protein Kinases
Protein from 1 animal in the CO-vent transplant group
had degraded and was excluded. IkBa degradation after
transplant occurred in both groups (Figure 3, A), but
was reduced by CO-vent treatment (P ¼ .0098). How-
ever, p65 localization to the nucleus by immunostaining
was increased to the same extent in both groups (not
shown).
All three MAPKs were activated 1 hour after LTX in both
groups (Figure 3, B-D). Activation of p38 (Figure 3, B) was
higher in CO-vent animals (P ¼ .0032). c-Jun N-terminal
kinase phosphorylation (Figure 3, C) was reduced in the
CO-vent group (n ¼ 5) compared with controls (n ¼ 5;
P¼ .0077). Extracellular signal-regulated kinase phosphor-
ylation (Figure 3, D) occurred after LTX with a negligible
difference in treatment group means (P ¼ .80). Each blot
image shown is representative of 5 or 6 independent blots.The Journal of Thoracic and CaReal-Time Reverse Transcription–Polymerase Chain
Reaction
One hour after LTX,HO-1 expression (Figure 4,A) was up-
regulated in both groups, much more so in the CO-vent group
(P ¼ .0314). Post-LTX IL-6 expression (Figure 4, B) in the
CO-vent group (n ¼ 5) was less (P ¼ .0192) compared with
the control group (n ¼ 5). Similarly, for IL-1b (Figure 4, C),rdiovascular Surgery c Volume 146, Number 2 431
FIGURE 2. Lung tissue cyclic guanosine monophosphate (cGMP). Mean
cGMP levels in transplanted lungs was increased in the carbon monoxide–
ventilated (CO-vent) group 1 hour after lung transplantation (*P ¼ .0358).
The mean  1 standard error is shown for controls (n ¼ 5) and CO-vent
(n ¼ 6).




Sa treatment effect was observed (P¼ .0262). The effect of CO
ventilation on post-LTX TNF-a expression (Figure 4, D) did
not differ significantly (P ¼ .087). Intercellular adhesion
molecule 1 transcription (Figure 4,E) increased in both groups
compared with fresh lung tissue, but a CO ventilation treat-
ment effect was not evident (P ¼ .99). Similarly, a treatment
effect was not detected (P ¼ .75) for endothelial nitric oxide
synthase transcription (Figure 4, F), iNOS transcription (not
shown), and B-cell lymphoma 2 (not shown).
Exploratory Results
Figure 5 shows a relationship between log10 IL-6 and
log10 IL-1bmRNA levels in posttransplant lung specimens,
and the impact of CO ventilation. This strong correlation
(r2¼ 0.98) implies that the signaling mechanism(s) respon-
sible for upregulating both cytokines is/are the same, and
that the mechanism(s) is/are equally inhibited by CO
ventilation.
Robustness of Results
For all but one of the outcomes variables, the results
reported here in terms of group means were found to be
robust with the use of alternative statistical methods. For
example, for IL-6, the easily detected post-LTX treatment
effect was statistically significant regardless of method;
P ¼ .0192 when comparing groups in terms of mean
IL-6, whereas P ¼ .047 when comparing group medians,
and P ¼ .010 when comparing group means on a log10
IL-6 scale. The exception was for cGMP; the primary result,
P¼ .036 for the post-LTX treatment effect in terms of mean
cGMP, may be tenuous after noting that P ¼ .093 for com-
parison of group medians (Wilcoxon test) and P ¼ .130 for
comparison of means on a log10 cGMP scale.
DISCUSSION
During the past decade, there has been increasing aware-
ness of the role of potentially toxic gases acting as important432 The Journal of Thoracic and Cardiovascular Surgintracellular second messengers, specifically NO, CO, and
H2S. An intriguing aspect of any of these endogenously
produced gaseotransmitters is that they can also be adminis-
tered exogenously as therapeutic agents directly into the lung
via the airwaywithout relying on perfusion for distribution to
the organ and cells of interest. At physiologic concentrations,
all 3 gases share similar biologic and pharmacologic proper-
ties. They are vasodilators and have anti-inflammatory and
cytoprotective effects.11 Endogenous CO is a by product of
heme metabolism produced by HOs. HO-2 is constitutive,
whereas HO-1 is a stress response gene induced by a variety
of cellular stresses. Carbon dioxide administered to the lung
can be transported by hemoglobin in blood to distant sites, or
can be dissolved in solutions for delivery to organs at the
time of retrieval or during ex vivo perfusion. Anti-
inflammatory effects of CO include induction of HO-1,
which has anti-inflammatory and antiapoptotic effects, pro-
duction of cGMP, and binding to heme-containing proteins,
including nicotinamide adenine dinucleotide phosphate oxi-
dase, cytochrome p450, cytochrome c, and iNOS, affecting
their activity, as reviewed elsewhere.11,12
Carbon monoxide has been studied extensively in models
of transplantation.13 McCurry’s group14 has studied the role
of CO comprehensively in animal models of conventional
lung transplant. This is the first demonstration of the benefit
of CO administration to lungs in a deceased NHBD. Our ob-
servations using NHBDs and EVLP are similar to those
reported byMcCurry’s group using a model of conventional
rat lung transplant and longer exposure to CO.14 Kohmoto
and colleagues14 showed that exposing donors (for 18 hours)
or donors and recipients (1 hour for donors and 24 hours for
recipients) to inhaled CO (250 ppm)was associatedwith im-
proved gas exchange and reduced leukocyte infiltration after
LTX. McCurry’s group studied mRNA at 2, 6, and 24 hours
after transplant, and found reductions in inflammatory cyto-
kines when CO was administered to both donor and recipi-
ents. Increased mRNA for inflammatory cytokines was
only observed 2 hours after LTX, confirming that this is an
early event in IRI.McCurry14 did not showNF-kBactivation
by electrophoretic mobility shift assay 2 hours after trans-
plant, but did show reduced intercellular adhesion
molecule 1 mRNA in CO-ventilated animals. Our evalua-
tions were at different time points after LTX. Although
p65 nuclear localization was similar by immunostaining 1
hour after LTX, the increased IkBa in lungs ventilated
with CO suggests NF-kB activation was reduced in the
CO-vent group. Phosphorylation of IkBa releases the nu-
clear subunits p65 and p50, which are transported to the nu-
cleus, where they bind to gene promoter sequences and
support transcription of a variety of inflammatory cytokines.
Phosphorylated IkBa is quickly ubiquinated and is therefore
reduced as a marker of NF-kB activation. Binding of the p65
subunit to the nucleus may be brief and transient, but IkBa
degradation persists until more protein is transcribed. Weery c August 2013
FIGURE 3. Western blots for nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IkBa) and mitogen-activated protein
kinases (MAPKs). Each graph is shown with a representative blot. A, IkBawas degraded in both carbon monoxide–ventilated (CO-vent) (n¼ 5) and control
(n ¼ 6) transplanted lungs, but less degradation was observed in the CO-vent group (*P ¼ .0098). B, p38 Activation was noted in the CO-vent (n ¼ 6) and
control (n¼ 5) groups but was more pronounced in the CO-vent group (yP¼.0032). C, c-Jun N-terminal kinase (JNK) activation was also observed in both
groups (n¼ 5 per group) and was reduced by the CO-vent treatment (yP¼ .0077). D, Extracellular signal-regulated kinase (ERK) activation was observed in
the CO-vent (n ¼ 5) and control (n ¼ 6) groups. The mean  1 standard error is shown for each group.




Salso showed evidence of reduced transcription of RNA for
some inflammatory cytokines (IL-1b, IL-6) in the CO-vent
group, consistent with reduced NF-kB activation.
Carbon monoxide ventilation was also associated with
increased p38 activation in our study. McCurry14 showed
that the protective effect of CO was largely abrogated by
administration of a p38 inhibitor, suggesting that p38 acti-
vation may have anti-inflammatory effects. The role of
p38 activation in inflammation is controversial. Administra-
tion of a p38 inhibitor prior to the onset of brain deathThe Journal of Thoracic and Caresulted in increased elaboration of inflammatory cytokines
in lung tissue.15 Like NO, CO stimulates guanylate cyclase
to increase cGMP. This is likely why CO ventilation in-
creased cGMP levels in transplanted lungs. Although
cGMP levels increased, this was not a result of changes in
iNOS or endothelial nitric oxide synthase, and appears to
be an independent impact of CO on guanylate cyclase. Cu-
riously, this increase in cGMP did not impact pulmonary
vascular resistance after LTX. Carbon monoxide ventilation
did not affect left:main PA blood flow, which suggests thatrdiovascular Surgery c Volume 146, Number 2 433
FIGURE 4. Reverse transcription-polymerase chain reaction (RT-PCR) for genes indicated. One hour after transplant, carbon monoxide ventilation (CO-
vent) was associated with increased upregulation of heme oxygenase-1 (HO-1þ) (*P ¼ .0314) (A), decreased upregulation of IL-6 (*P ¼ .0192, n ¼ 5 per
group) (B), and decreased upregulation of interleukin 1-beta (IL-1b) (*P ¼ .0262, n ¼ 6 per group) (C). The 2 treatment groups were similar in regard to
upregulation of tumor necrosis factor-alpha (TNF-a) (P¼ .087) (D), upregulation of intercellular adhesion molecule-1 (ICAM-1) (P¼ .99) (E), and down-
regulation of endothelial nitric oxide synthase (eNOS) (P ¼ .75, n ¼ 5 CO-vent and n ¼ 6 controls) (F). For each of A through F, for at least 1 of the 2
treatments, the post–lung transplant mean was statistically significantly different from the mean for fresh tissue samples.




Spulmonary vascular resistance of the graft was not affected
by CO ventilation.
In this study, we showed that CO administered to a Maas-
tricht category I NHBD begun 1 hour after death, during
EVLP, and for 1 hour after LTX, reduced edema formation434 The Journal of Thoracic and Cardiovascular Surgduring EVLP, and had a beneficial effect on oxygenation of
the graft. The reason less edema occurred during EVLP in
CO-treated lungs is unclear. As done with NO treatment of
NHBDs,we subjected human pulmonarymicrovascular endo-
thelial cells (HMVECs) to simulated cold IRI. Exposure ofery c August 2013
FIGURE 5. Scatter plot of log10-transformed interleukin-6 (IL-6) and
interleukin-1 beta (IL-1b) messenger RNA pairs from carbon monoxide–
ventilated (squares) and control (circles) post-transplant lung samples.
Near-perfect correlation (r2 ¼ 0.98) suggests that the signaling pathway(s)
responsible for upregulation of IL-6 and IL-1b post-transplant are likely
identical and equally inhibited by CO-ventilation.




SHMVECs to 500 ppm CO for 1 hour before exposure to cold
Perfadex had no impact on inter-endothelial gap formation (re-
sults not shown). This was unlike what we observed with NO
administration, in which exposure of HMVECs to 40 ppmNO
reduced inter-endothelial cell gap formation after warm cell
culture media was replaced with cold Perfadex.9
We showed that HO-1 mRNA was maintained in
CO-ventilated lungs, but was reduced in control lungs, sug-
gesting that exogenousCO inducesHO-1 expression, or pre-
vents downregulation. Exogenous CO can substitute for
endogenous HO-1 in preventing hepatic IRI.16 HO-1–defi-
cient mice had much more severe injury than wild-type con-
trols subjected to 1 hour left hilar clamp.17 Paradoxically,
injury was reduced by 24-hour exposure to 0.1% CO prior
to ischemia. Clearly, the protective effect of CO was inde-
pendent of HO-1 in these knockout mice. HO-1 has shown
anti-apoptotic potential, probably a result of the inhibition
of the pro-apoptotic c-JNK activation.12 Although we
showed that CO ventilation reduced JNK activation, we
found no difference in B-cell lymphoma 2 expression be-
tween the CO-vent and control groups, perhaps because of
the short reperfusion time.
Ex vivo lung perfusion is increasingly used to evaluate
lungs initially judged unsuitable for transplant. In addition
to Steen’s6 and Keshavjee’s7 favorable experience, initial
reports from Zych and colleagues18 and Aigner and col-
leagues19 are encouraging. Ex vivo lung perfusion was used
to evaluate lungs retrieved fromacategory IINHBD, resulting
in a successful LTX.19 Ex vivo lung perfusion may allow forThe Journal of Thoracic and Casafe LTX using lungs retrieved fromNHBDs on a large scale.
Keshavjee’s group20 showed the potential to repair injured do-
nor lungs during EVLP using gene therapy. Thus, EVLP of-
fers an opportunity to treat lungs to reduce IRI when the
organ is subsequently transplanted.
There is growing interest in expanding the donor pool by
harvesting lungs from DCDs. Unfortunately, DCD lung
transplant activity has increased only modestly during the
past 10 years, and DCDs contribute only about 2% of all
lungs transplanted in the United States.21 However, the num-
ber ofMaastricht category I NHBDs is very large—in excess
of 750,000 annually. Although many of these sudden deaths
will be in older patients, or the lungs may be unsuitable for
other reasons, if only a small fraction (5%, n  35,000) of
sudden death victims had lungs that could be retrieved and as-
sessed for LTX, the impact would be enormous. Even though
not all sudden cardiac arrests are attended by emergency
medical services,>300,000 sudden deaths have cardiopul-
monary resuscitation by emergency medical services. Only
7% are resuscitated successfully for transport. The median
age of victims of sudden cardiac death is only 60 years
old,22 so nationally there are tens of thousands of potential
lung donors from this source. This represents a huge potential
untapped source of lungs for transplant. The feasibility of
lung transplant from NHBDs has been demonstrated in ani-
mal models by us and others,1,23 and a small experience
has accumulated in humans.3,24 We are beginning to
evaluate lungs retrieved from category I NHBDs with
EVLP (www.clinicaltrials.gov, trial no. NCT01615484).
Thus, investigating strategies to improve function of lungs
retrieved from NHBDs is critically important.
Because there will be an interval of time after death of
a human category I NHBD before consent is obtained for
lung retrieval for transplant consideration, we left the
NHBD animals nonventilated for 1 hour. Human NHBDs
could be ventilated during transport for lung retrieval, so
there would be opportunities for therapeutic ventilation.
We have shown that lung transplant from NHBDs is feasi-
ble, but can be associated with pulmonary edema and
increased pulmonary vascular resistance, presumably
resulting from IRI.2,25 A unique feature of lungs
compared with other solid organs that are transplanted is
that the airway facilitates therapeutic access to the lung to
deliver pharmacologic agents, or ‘‘second-messenger’’
gases. In previous studies (summarized by Egan26), we
showed that ventilating lungs after death with oxygen alone
resulted in slower onset of necrosis, ultrastructural damage,
maintenance of adenosine triphosphate levels, and delayed
onset of increased filtration coefficient.
Ischemia–reperfusion injury is the most likely reason for
primary graft dysfunction, a major cause of morbidity
and the leading cause of mortality early after LTX.
Lung IRI is characterized by early pulmonary edema and
upregulation of cellular adhesion molecules, elaborationrdiovascular Surgery c Volume 146, Number 2 435




Sof cytokines, and an inflammatory phenotype. Primary graft
dysfunction is also correlated with the risk of developing
bronchiolitis obliterans syndrome. Thus, preventing or
reducing IRI may have profound implications for both early
function and mortality following LTX from conventional
donors, as well as long-term survival after LTX from con-
ventional donors or NHBDs.
Study Limitations
Our study has limitations. We chose to terminate our
study 1 hour after LTX to interrogate lung tissue for signal-
ing pathway activation and evidence of early gene transcrip-
tion. Longer follow-up studies could determine whether the
reduction in cytokine mRNA leads to less IRI. We adminis-
tered CO at several times. Additional studies would help de-
termine whether CO administration during EVLP alone
would be beneficial. Kohmoto and colleagues14 showed ad-
ministration of CO to conventional donors resulted in
improved gas exchange, but had little impact on inflamma-
tory cytokines after transplant. Long-term therapy of a re-
cipient with CO may be impractical because CO binds
irreversibly to hemoglobin and might eventually interfere
with oxygenation. However, ventilation of lungs in an
NHBD and during EVLP would likely have no detrimental
effect on the recipient and might be beneficial, particularly
if it reduced inflammation post-LTX by reducing NF-kB
and JNK activation. We chose to study only 1 dose of
CO. Dose–response studies would be necessary prior to
clinical application.
CONCLUSIONS
Our study adds to a growing body of evidence that CO, in
addition to participating as a critical secondmessenger, may
have an important therapeutic role. This is the first study to
use CO in NHBDs, which highlights the potential to use the
airway in an NHBD as a therapeutic avenue.
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TABLE E1. Primers used in real-time reverse transcription–polymerase chain reaction
Gene Primer sequences 50/30 Gene accession no. PCR product size, bp
HO-1 Forward: CACAAAGACCAGAGTCCCTCACAG NM_012580 187
Reverse: AAATTCCCACTGCCACGGT
IL-6 Forward: CAAGAGACTTCCAGCCAGTT NM_012589 510
Reverse: CCATTAGGAGAGCATTGGAAG
IL-1b Forward: GTGGCAGCTACCTATGTCTT M98820 596
Reverse: GCCATCTTTAGGAAGACACG
TNF-a Forward: GAGAAGTTCCCAAATGGGCT NM_012675 203
Reverse: ATCTGCTGGTACCACCAGTT
ICAM-1 Forward: GGAGATCACATTCACGGTGC NM_012967 500
Reverse: CACACTTCACAGTTACTTGGT
eNOS Forward: CACTGCTAGAGGTGCTGGAA NM_021838 492
Reverse: AGGACTTGTCCAAACACTCC
b-actin Forward: CATGGATGACGATATCGCTG NM_031144 408
Reverse: GGATGGCTACGTACATGGCT
PCR, Polymerase chain reaction;HO-1, heme oxygenase 1; IL, interleukin; TNF, tumor necrosis factor; ICAM-1, intercellular adhesion molecule 1; eNOS, endothelial nitric oxide
synthase.
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